Cytokinetics Stock News

CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.

Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q2 2021 Results - Earnings Call Transcript

Cytokinetics (CYTK) delivered earnings and revenue surprises of -32.31% and -49.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Cytokinetics (NASDAQ:CYTK) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 26.47% over the past year to ($0.86), whi

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 30, 2021 it granted stock options to purchase an aggregate of 258,

Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Declineof SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500

SOUTH SAN FRANCISCO, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 5, 2021 at 4:00

SOUTH SAN FRANCISCO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced the pricing of an underwritten public offering of 10,000,000 shares of its commo

Cytokinetics Incorporated (NASDAQ: CYTK) shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments from analysts. On Tuesday, B

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term

SOUTH SAN FRANCISCO, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced plans to offer, subject to market and other conditions, $200,000,000 of shares o

Today, Cytokinetics Incorporated (NASDAQ: CYTK) reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks resulted in substantial and statistically significant reductions i

The stock price of Cytokinetics, Inc. (NASDAQ: CYTK) increased by over 63% during intraday trading. This is why it happened.